Arcutis Biotherapeutics Stock Fundamentals
| ARQT Stock | USD 12.25 0.52 4.07% |
Arcutis Biotherapeutics fundamentals help investors to digest information that contributes to Arcutis Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Arcutis Stock. The fundamental analysis module provides a way to measure Arcutis Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arcutis Biotherapeutics stock.
At this time, Arcutis Biotherapeutics' Interest Expense is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 182.2 M in 2024, despite the fact that Net Loss is likely to grow to (254.5 M). Arcutis | Select Account or Indicator |
Arcutis Biotherapeutics Company Current Valuation Analysis
Arcutis Biotherapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Arcutis Biotherapeutics Current Valuation | 1.37 B |
Most of Arcutis Biotherapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arcutis Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Arcutis Current Valuation Historical Pattern
Today, most investors in Arcutis Biotherapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arcutis Biotherapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Arcutis Biotherapeutics current valuation as a starting point in their analysis.
Arcutis Biotherapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Arcutis Biotherapeutics has a Current Valuation of 1.37 B. This is 90.45% lower than that of the Biotechnology sector and 70.46% lower than that of the Health Care industry. The current valuation for all United States stocks is 91.75% higher than that of the company.
Arcutis Biotherapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arcutis Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Arcutis Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arcutis Biotherapeutics competition to find correlations between indicators driving Arcutis Biotherapeutics's intrinsic value. More Info.Arcutis Biotherapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Arcutis Biotherapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Arcutis Biotherapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Arcutis Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcutis Biotherapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcutis Biotherapeutics could also be used in its relative valuation, which is a method of valuing Arcutis Biotherapeutics by comparing valuation metrics of similar companies.Arcutis Biotherapeutics is currently under evaluation in current valuation category among its peers.
Arcutis Biotherapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arcutis Biotherapeutics from analyzing Arcutis Biotherapeutics' financial statements. These drivers represent accounts that assess Arcutis Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arcutis Biotherapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 830.3M | 1.0B | 1.0B | 223.9M | 257.4M | 244.6M | |
| Enterprise Value | 767.3M | 943.2M | 1.0B | 341.4M | 392.6M | 373.0M |
Arcutis Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcutis Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcutis Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Arcutis Fundamentals
| Return On Equity | -1.92 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (1.41) % | ||||
| Operating Margin | (0.87) % | ||||
| Current Valuation | 1.37 B | ||||
| Shares Outstanding | 117.05 M | ||||
| Shares Owned By Insiders | 2.14 % | ||||
| Shares Owned By Institutions | 97.86 % | ||||
| Number Of Shares Shorted | 23.53 M | ||||
| Price To Book | 9.15 X | ||||
| Price To Sales | 10.78 X | ||||
| Revenue | 59.61 M | ||||
| Gross Profit | 2.93 M | ||||
| EBITDA | (227.43 M) | ||||
| Net Income | (262.14 M) | ||||
| Cash And Equivalents | 282.17 M | ||||
| Cash Per Share | 5.47 X | ||||
| Total Debt | 205.92 M | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 10.75 X | ||||
| Book Value Per Share | 1.34 X | ||||
| Cash Flow From Operations | (247.06 M) | ||||
| Short Ratio | 10.26 X | ||||
| Earnings Per Share | (1.67) X | ||||
| Price To Earnings To Growth | (0.31) X | ||||
| Target Price | 19.0 | ||||
| Number Of Employees | 296 | ||||
| Beta | 1.19 | ||||
| Market Capitalization | 1.49 B | ||||
| Total Asset | 341.37 M | ||||
| Retained Earnings | (981.9 M) | ||||
| Working Capital | 283.76 M | ||||
| Current Asset | 87.18 M | ||||
| Current Liabilities | 4.42 M | ||||
| Net Asset | 341.37 M |
About Arcutis Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcutis Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcutis Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcutis Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 59.6 M | 62.6 M | |
| Cost Of Revenue | 5 M | 5.2 M | |
| Stock Based Compensation To Revenue | 0.65 | 0.62 | |
| Sales General And Administrative To Revenue | 29.82 | 26.50 | |
| Research And Ddevelopement To Revenue | 1.86 | 1.76 | |
| Capex To Revenue | 0.01 | 0.01 | |
| Revenue Per Share | 0.86 | 0.90 | |
| Ebit Per Revenue | (4.04) | (4.25) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.